Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
MitoRx Therapeutics
United Kingdom
- Oxford, Oxfordshire
- 15/12/2023
- Seed
- $4,000,000
MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.
- Industry Biotechnology Research
- Website https://www.mitorxtherapeutics.com/
- LinkedIn https://www.linkedin.com/company/mitorx-therapeutics/about/
Related People
Jon ReesFounder
United Kingdom -
Greater Oxford Area
Jon is an entrepreneurial, innovation and investment-focused life sciences PhD & tenacious leader with deep strategic insight. He can draw on a vast personal network within the investment and drug development industries. Jon founded his fourth company, MitoRx Therapeutics, in 2021.
Jon did his post-doc engineering primary metabolism at the University of Oxford, has a PhD in metabolic engineering from the Royal Holloway University of London, a Masters with Distinction from LJMU and a BSc from University of Manchester Institute for Science and Technology. May consider non-executive director positions.
CipherOwl | $15,000,000 | (Oct 24, 2025)
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
OneAM | $4,700,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)